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Abstract
Background: This is an incident series of ﬁve dialysis patients with late-diagnosed calciﬁc uraemic arteriolophathy (CUA),
severe uncontrolled hyperparathyroidism and infected skin ulcerations.
Methods: A multimodal intervention was based on wound care, antibiotics, surgical debridement, sodium thiosulphate and
cinacalcet and associatedwith regression of skin disease in four cases after varying treatment time periods ranging from 4 to 33
months.
Results: Multimodal treatment including sodium thiosulphate and cinacalcet was associated with very favourable local
outcomes and survival. This series further conﬁrms that the diagnosis of CUA is rarely made at the nodular, non-ulcerative
phase of the disease.
Conclusions: This series contributes to the build-up of case series reporting on the treatment of CUA, andwill hopefully serve as
a basis ofwell-conceived comparative effectiveness studies investigating the value of the combined interventions applied so far
in this severe condition.
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Introduction
Calciﬁc uraemic arteriolopathy (CUA) is a severe systemic disease
with short survival characterized by progressive calciﬁcation of
arterioles leading to local ischaemia and thrombosis [1]. The clin-
ical phenotype of this arteriolopathy in part overlaps with that of
other diseases and this condition is often diagnosed only at the
advanced, ulcerative stage rather than at the more precocious
nodular phase characterized by the presence of non-ulcerated
calciﬁed skin plaques [2]. CUA is multifactorial in nature
and hyperparathyroidism, excessive vitamin D administration,
hyperphosphataemia, inﬂammation and deﬁciency of inhibitors
of vascular calciﬁcation are held as major factors responsible for
this devastating disease [3]. Female gender, diabetes, obesity, a
pro-coagulant state, the use of warfarin and hypoalbuminaemia
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are considered as important predisposing risk factors and/or as
disease accelerators [2, 4] in dialysis patients. Owing to themulti-
factorial nature of this calciﬁc disease, experts’ recommenda-
tions in the most accessed electronic source of evidence-based
information [4] suggest a combined therapeutic approach includ-
ing intensive wound care and avoidance of skin trauma, correc-
tion of hyperphosphataemia, sodium thiosulphate, low calcium
dialysate, oxygen therapy and adequate treatment of hyperpara-
thyroidism, with surgery in the most severe, refractory cases or
with cinacalcet in less severe cases responsive to this drug. How-
ever, given the rarity of CUA, there are no randomized trials
underpinning these recommendations. As commonly occurs in
rare diseases [5], the building of knowledge on this condition
rests on well-conceived registries [6] and on careful interpret-
ation of case series. Recent post hoc analyses in the frame-work
of the Evaluation of Cinacalcet Hydrochloride Therapy to Lower
Cardiovascular Events (EVOLVE) trial [7] suggest that cinacalcet
may reduce the incidence rate of CUA in the dialysis population.
Information on clinical outcomes in patients treated by the cur-
rently recommended combined approach including cinacalcet
[4] remains mainly based on single case reports [8–22] or on
small clusters of three to seven patients [23–26], the largest series
published so far being composed of 27 patients collected in a na-
tional effort by Austrian nephrologists [24]. Early studies were
mainly centred on cinacalcet [8–12, 14, 16], while subsequent
studies focused on combined treatment including thiosulphate
[10, 13, 18–21, 23–26]. Furthermore, variable policies were applied
in these studies for the use of non-calcium-based phosphate bin-
ders, low calcium dialysate, active forms of vitamin D [17] and
oxygen therapy [21, 23, 25].
Accruing information on carefully designedmultimodal ther-
apies including cinacalcet in studies at single institutions is of
relevance to gain further non-experimental insights on the efﬁ-
cacy of these approaches and to enlarge the collection of treated
cases for future systematic reviews and comparative effective-
ness studies. In this perspective,we report a series ofﬁve patients
where the diseasewas diagnosed at an advanced phase. All these
patients were treated according to amultimodal therapy, includ-
ing sodium thiosulphate and cinacalcet, as well as with the full
series of interventions (avoidance of calcium binders and vita-
min D, stopping warfarin, low calcium dialysate; intensive dialy-
sis; careful wound care and broad-spectrum antibiotics) that
current literature indicates as possibly useful for the manage-
ment of this disease [4]. Owing to logistic reasons, our approach
excluded oxygen therapy.
Materials and methods
Case 1
A 33-year-old obese female was admitted to our department for
renal graft failure 13 years after transplantation. She had a history
of long-term treatment with warfarin because of inferior cava hy-
poplasia, hyperparathyroidism [parathyroid hormone (PTH)
≥1000 pg/mL on multiple testing], hyperphosphataemia and
hypocalcaemia. On admission, large skin ulcers were present on
both legs. She presented multiple painful subcutaneous nodules,
which had been interpreted as a sign of polyarteritis nodosa,
and she had received a short course of prednisone and cyclophos-
phamide. A skin biopsy made at admission documented CUA.
Case 2
A68-year-oldmale on continuous ambulatory peritoneal dialysis
exhibited bilateral skin ulcers and painful nodules on both legs
and an ulcer on glans penis which had been interpreted as a neo-
plastic lesion. On histology, the glans lesion showed extensive
calcium deposits in the lumen of a small-sized vessel which
were pathognomonic of CUA. This patient had a history of very
poor compliance to therapeutic prescriptions and severe, uncon-
trolled hyperparathyroidism.
Case 3
A 67-year-old diabetic female on haemodialysis presentedwith a
painful ulcerated nodule, which was initially interpreted as a
consequence of peripheral artery disease. New ulcers appeared
on contralateral calf in the subsequent weeks. She had been
treatedwithwarfarin formany years because of atrial ﬁbrillation.
She had uncontrolled hyperparathyroidism (PTH persistently
≥1000 pg/mL), hyperphosphataemia and hypocalcaemia.
Case 4
A65-year-old femalehadinitiatedhaemodialysis5yearsearlier.She
was admitted to our department because of the presence of large
symmetrical infectedulcerson lower limbs.Ulcershadbeenconsid-
eredas anexpressionofperipheral arterydisease. Thepatienthada
history of scarce compliance to treatments applied to control bone
mineral disorders with severe, uncontrolled hyperparathyroidism
andwas on long-term treatmentwithwarfarin for atrial ﬁbrillation.
Case 5
A68-year-old diabetic femalewhohad been onhaemodialysis for
4 years was hospitalized for painful subcutaneous indurations in
the thighs and infected ulcers on both calves which had been at-
tributed to diabetes and peripheral artery disease. During the
year preceding the appearance of these ulcers, the patient had
decided to stop all medications. The diagnosis of CUAwas made
on clinical grounds because of uncontrolled hyperparathyroidism.
Multimodal treatment of CUA
In all cases, we applied a standard multimodal treatment proto-
col contemplating immediate treatment with cinacalcet. This
drug was initiated at starting dose of 30 mg/day and the dosage
was increased every other day up to the maximal tolerated
dose and under strict monitoring of serum calcium concentra-
tion. Intravenous sodium thiosulphate infusion was initiated
4–8 weeks after cinacalcet; this gap was due to delivery time
from manufacturer. Sodium thiosulphate was administered
intravenously at an initial test dose of 12.5 g. The drug was then
continued with a standard dose (25 g administered during
the last 30 min of each haemodialysis session). Sodium thiosul-
phate treatment was prolonged until ulcer healing plus an
additional 2 months. Furthermore, along with current recom-
mendations [4], our multimodal approach contemplated: with-
drawal of calcium-containing phosphate binders and vitamin D
compounds; replacement of warfarin with subcutaneous hep-
arin; reduction of dialysate calcium concentration (1.25 mmol/
L); increased number and/or duration of dialysis sessions; and
wound management with atraumatic resection of necrotic skin
and administration of broad-spectrum antibiotics.
All patients gave informed consent concerning off-label use of
sodium thiosulphate. Procedures were conducted in adherence
to the Declaration of Helsinki.
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Results
The demographic, clinical and biochemical data of this series are
summarized in Table 1.
Patientswere on stage G5D chronic kidney disease and all had
been on regular dialysis treatment for periods ranging from 3 to
72 months. All presented with advanced, infected skin lesions.
All cases had biochemical evidence of severe hyperparathyroid-
ism (Table 2). Female gender (all but one cases), obesity (Cases
1 and 5), diabetes (Cases 3 and 5) and warfarin treatment
(Cases 1, 4 and 5) were obvious risk factors for calciphylaxis in
most cases (Table 1). In all cases of this series, the diagnosis of
CUA had been missed before referral to our unit (Table 1) and
none of these patients had been treated with cinacalcet or so-
dium thiosulphate.
A favourable response to themultimodality treatmentwas re-
gistered after various periods of treatment in all but one patient
(Case 2). In this patient, the multimodal therapy was stopped
after 30 months because after an initial, brief period of compli-
ance, the patient refused thiosulphate treatment and continued
to show poor adherence to cinacalcet, phosphate binders and to
the prescribed dialysis schedule aswell as to suggested parathyr-
oidectomy, so that his hyperparathyroidism remained uncon-
trolled. In the other four patients, skin ulcerations healed after
an average period of 18.7 ± 11.9 months (range: 4–33 months).
After the healing of skin lesions, these patients had an additional
follow-up of 19.2 ± 3.8months (range: 15–24months). During this
observation period, no skin ulceration relapses were registered.
All patients, including the one with unabated hyperparathyroid-
ism, poor therapeutic compliance and persisting skin ulcers, are
still alive and on dialysis treatment. At last follow-up visit
(Table 2), hyperparathyroidism was well controlled in the four
patients with healed skin ulcerations.
Discussion
In the present series of ﬁve dialysis patients with advanced, late-
diagnosed CUA, a multimodal intervention, including wound
care, antibiotics, sodium thiosulphate and cinacalcet, was asso-
ciated with full regression of skin lesions in four cases after vari-
able treatment periods ranging from 4 to 33 months. This
favourable clinical course paralleled with almost full regression
of hyperparathyroidism. The patient unresponsive to this multi-
modal therapy was overtly non-compliant and presented un-
abated hyperparathyroidism across a 30-month follow-up. All
patients survived over global follow-up periods ranging from 24
to 48 months.
CUA is a complex, multifactorial disease. Hyperparathyroid-
ism is held as amajor causal component of this deadly condition
[27] and severe hyperparathyroidism was a hallmark in our ser-
ies. Several factors may either trigger or exacerbate this disease,
and in line with previous studies [1, 2] obesity, diabetes and war-
farin exposure were possible inciting factors or disease accelera-
tors in our series.
Early diagnosis and timely treatment of risk factorsmay, in the-
ory, limit the aggressiveness of CUA.However, the diagnosis of this
disease is frequently overlooked and, in most cases, the diagnosis
is made at the advanced, ulcerative stage only [2], which dictates a
very short survival. In all cases, we describe here that the correct
diagnosis was omitted and skin lesions were initially attributed
to peripheral artery disease, panniculitis or cancer.
Even though no historical series exist to support the conten-
tion that survival and clinical outcomes have improved over
the last decade, it is the prevailing view that greater focus on
wound care, aggressive treatment of hyperparathyroidism, the
use of thiosulphate and perhaps oxygen therapy [4] improved
the outlook of patients with this disabling disease characterized
by an ominous prognosis.
In general, the contribution of single components of multi-
modal therapies to clinical outcomes is difﬁcult to dissect. This
is particularly true in small series like ours. Sodium thiosulphate
is held as a major disease-modifying agent in CUA [24, 28]. Its fa-
vourable action is generally attributed to calcium chelation and
possibly to inhibition of vascular calciﬁcation in injured blood
vessels [28]. However, sodium thiosulphate treatment has no ef-
fect on hyperparathyroidism, which is a relevant underlying cau-
sal factor in CUA. In the largest cases series published so far [23,
24], the combined use of thiosulphate and cinacalcet associated
with complete regression of skin lesions in six of seven cases in
the series of Canadian patients by Baldwin et al. [23] and with a
52% (complete) and 19% (partial) regression rate of the same le-
sions in the Austrian series by Zitt et al. [24]. In this second series,
Table 1. Demographic, clinical and biochemical characteristics
Patient number 1 2 3 4 5
Age (years) 33 68 67 65 68
Gender Female Male Female Female Female
Type of dialysis HD HD/PD HD HD HD
Dialysis vintage (months) 3 72 66 60 50
Obesity Yes No No No Yes
Diabetes No No Yes No Yes
First diagnosis Panniculitis
polyarteritis
Glans penis
carcinoma
Diabetic peripheral
artery disease
Peripheral artery
disease
Diabetic peripheral
artery disease
Proximal skin lesions No No No No No
Distal skin lesions Yes Yes Yes Yes Yes
Treatment with vitamin D compounds Yes Yes Yes Yes Yes
Calcium-based phosphate binders Yes No No Yes Yes
Warfarin Yes No Yes Yes No
PTH (pg/mL) 1150 1700 1000 1100 980
Calcium (mg/dL) 9.4 11.0 10.0 10.5 10.0
Phosphate (mg/dL) 4.8 5.5 3.4 4.9 5.9
HD, haemodialysis; PD, peritoneal dialysis.
110 | D. Russo et al.
C
L
IN
IC
A
L
K
ID
N
E
Y
JO
U
R
N
A
L
the largest study reporting on the treatment of calciphylaxis,
the use of antibiotics and cinacalcet were relevant predictors of
a favourable clinical response. Nevertheless, the death rate in
Austrian patients was as high as 52% over an average 3-month
follow-up, which is substantially higher than in Canadian pa-
tients where the death rate was 25% during an average follow-
up of ∼20 months. In these studies, the use of cinacalcet was
apparently related in an inverse fashion with the death risk, be-
cause this drug was used in 30% of patients in the Austrian study
[24] and in 57% of patients [23] in the Canadian study. Along with
this hypothesis, in our study, the effect on skin lesions of the
multimodality approach contemplating cinacalcet as a ﬁxed
component was very good, with an 80% remission rate (four of
ﬁve patients) and all patients surviving over follow-up periods
extended up to 48 months. However, survival data in small stud-
ies are per se hardly interpretable. In this respect, the quite long
survival (censoring period 30months) in the patient uncompliant
to the multimodal treatment in our study indicates that survival
may be unexpectedly long also in patients with unremitting
hyperparathyroidism.
Our study has limitations and strengths. The fact that the dis-
ease was diagnosed at an advanced stage (negative selection)
might have in theory hindered the response to therapy. However,
the remission rate of skin lesions and the survival rate of our
patients were remarkably high. Another important limitation is
the fact that we corroborated the diagnosis of calciphylaxis
with histology in just two cases. For the risk posed by severe
ulcer infection, the diagnosis in remaining cases was made just
on clinical criteria. Indeed, deﬁnitive diagnosis of calciphylaxis
requires a skin biopsy to exclude other conditions that can
mimic CUA; skin biopsy, however, may expose patients to pos-
sible risks such as ulceration, superimposed infection, propaga-
tion of new lesions, bleeding and induction of necrosis [29];
these risks may be reduced by performing punch biopsy rather
than an incisional biopsy [29] and, when possible, in a non-ul-
cerative phase of the disease, in our opinion.
The strengths of our study are the fact that it is based on a sin-
gle institution and on a pre-established multimodal therapeutic
approach which was uniformly applied to all cases. Overall, our
observations are compatible with the hypothesis that a multi-
modal regimen including a drug, which effectively counters
hyperparathyroidism, may prompt a very favourable response
in patients with CUA, a hypothesis in line with the recent ob-
servation that long-term cinacalcet treatment substantially
prevents the occurrence of CUA in dialysis patients [7].
In conclusion, the present case series further conﬁrms that
the diagnosis of CUA in dialysis patients is rarely made at the
nodular, non-ulcerative phase [2] of the disease. Themultimodal
treatment applied in the present study was associated with very
favourable local outcomes and survival. This series adds to previ-
ous observations and contributes to the information build-up
that will hopefully serve as a basis for well-conceived compara-
tive effectiveness studies investigating the value of the combined
interventions applied so far.
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